News Articles and Montana BioScience Alliance Newsletters
New technology developed by researchers at Montana State University, featured this month on the cover of the journal Science Advances, could have powerful impacts on the way scientists study viruses, make vaccines or splice genes.
For a fifth straight year, Montana State University recorded an all-time high for research expenditures — the funding put toward scientific discovery and other scholastic and creative pursuits. MSU is the largest research enterprise in the state, and its total expenditures exceed the research expenditures of all other institutions in the state combined.
Central Montana Medical Center has broken ground on a $15.6 million cancer center that will bring comprehensive cancer care services to central Montana. That means residents living in central and northern Montana won’t have to travel as long for cancer treatment.
A vaccine to prevent overdosing on fentanyl and one for heroin are in the works at the University of Montana and partner institutions. Human trials are expected to start in early 2024 for both vaccines, according to UM.
Only three years after its creation, the University of Montana and University of Montana Foundation today announced a significant investment to benefit the L.S. Skaggs Institute for Health Innovation. Known as SIHI, the institute will use this investment to expand its influence as a statewide hub for health education, research and outreach — with a goal of improving access to emerging health innovations for all Montanans.
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.